Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative punishment against Beijing Orient Telecom Science & Technology Co., Ltd. (*ST Dongtong*) for suspected false reporting of financial data, indicating serious violations of securities laws and regulations [1][3]. Group 1: Financial Misconduct - *ST Dongtong* has inflated its revenue and profits for four consecutive years, leading to significant legal repercussions [3]. - The CSRC plans to impose a fine of 229 million yuan on the company and a total of 44 million yuan on seven responsible individuals [3]. - The actual controller of *ST Dongtong* faces a 10-year ban from the securities market due to these violations [3]. Group 2: Potential Consequences - The company is suspected of major illegal activities that could lead to mandatory delisting, prompting the Shenzhen Stock Exchange to initiate delisting procedures [3]. - The CSRC will transfer any potential criminal evidence to the public security authorities in accordance with relevant legal standards [3]. Group 3: Market Impact - As of September 12, *ST Dongtong*'s stock price closed at 6.58 yuan, reflecting a decline of over 56% year-to-date, with a total market capitalization of 3.671 billion yuan [4].

记者丨黎雨桐 对于可能涉及的犯罪线索，证监会将坚持应移尽移的工作原则，严格按照《刑法》《最高人民检察院公安部关于公安机关管辖的刑事案件立案 追诉标准的规定（二）》的规定移送公安机关。 编辑丨吴桂兴 截至9月12日收盘，*ST东通股价报收6.58元，年内跌超56%，总市值36.71亿元。 据证监会网站消息，近日，证监会对深交所创业板上市公司北京东方通科技股份有限公司（简称*ST东通）涉嫌定期报告等财务数据存在虚假 记载作出行政处罚事先告知。 （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品 | 2 1财经客户端 南财快讯工作室 编辑 | 黎雨桐 实习生林芷仪 六个核桃卖不动了，前衡水首富转身搞起半导体 西贝承认部分菜品是隔夜菜 深圳罗湖二手房签约量激增109% SFC 21君荐读 经查，ST东通连续四年虚增收入和利润，违反证券法律法规。证监会拟对上市公司罚款2.29亿元，对7名责任人合计罚款4400万元，对实际控 制人采取10年证券市场禁入。ST东通涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 ...

Core Viewpoint - *ST Gaohong has faced significant stock price declines, with a continuous drop for 20 trading days, closing at 0.8 yuan per share as of September 5 [1] Group 1: Stock Price and Trading Activity - The company has experienced a continuous decline in stock price, with a 20-day trading halt, indicating severe market concerns [1] - As of September 1, the stock price fell below 1 yuan, raising the risk of delisting due to trading rules [6] Group 2: Regulatory Issues and Financial Irregularities - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for inflating revenue and profit figures from 2015 to 2023, with inflated revenues totaling 6.94 billion yuan to 56.34 billion yuan across various years [4] - The CSRC's notice also indicated that the company had engaged in fraudulent issuance of shares during its non-public offering in 2021, raising 1.25 billion yuan based on false financial data [5] - The cumulative litigation and arbitration amount against the company stands at 3.176 billion yuan, which is 386.88% of the latest audited consolidated net assets [6]

关于公司股票可能被实施重大违法强制退市的第五次风险提示 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 证券代码：000851 证券简称：*ST 高鸿 公告编号：2025-112 大唐高鸿网络股份有限公司 罚字〔2025〕62 号）。根据收到的《行政处罚事先告知书》认定情况，公司 2015 年至 2023 年年度报告分别虚增营业收入 6.94 亿元、24.52 亿元、24.20 亿元、 占各期披露营业收入的 9.34%、28.27%、26.97%、35.18%、49.38%、35.38%、21.11%、 亿元、56.12 亿元、24.68 亿元、17.96 亿元、7.32 亿元、3.86 亿元;分别虚 增利润总额 67.36 万元、243.88 万元、242.24 万元、1,282.80 万元、2,190.52 万元、1,542.38 万元、894.46 万元、370.74 万元、788.21 万元，占各期披露 利润总额绝对值的 0.42%、1.44%、0.99%、13.56%、64.88%、11.35%、22.11%、 与此同时，《行政处罚事先告知书》 ...

证券代码：839680 证券简称：*ST 广道 公告编号：2025-082 深圳市广道数字技术股份有限公司 关于公司股票可能被实施重大违法强制退市的第十三次风险提 示公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 特别提示：公司存在重大违法强制退市风险。深圳市广道数字技术股份有限 公司（以下简称"公司"）于 2024 年 12 月 4 日被中国证券监督管理委员会（以下 简称"中国证监会"）立案调查。公司于 2025 年 6 月 13 日收到中国证券监督管理 委员会《行政处罚事先告知书》（【2025】12 号）（以下简称"《告知书》"）， 根据《告知书》认定情况，公司可能被实施重大违法强制退市。根据《北京证券 交易所股票上市规则》10.5.4 条，在被实施退市风险警示期间，收到相关行政处 罚决定书，可能触及重大违法类强制退市情形的，公司将及时披露有关内容，并 于公告披露日的次一交易日起长期停牌，直至北京证券交易所将依法依规作出是 否终止公司股票上市的决定。根据《北京证券交易所股票上市规则》第 10. ...

公司于 2025 年 2 月 26 日收到中国证监会《立案告知书》（证监立案字 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督管理委员 会立案告知书暨风险提示公告》（公告编号：临 2025-007）。 （处 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-102 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第九次风险提示公告 正式处罚决定为准。敬请广大投资者关注后续公告并注意投资风险。 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上 市规则》的相关规定，作出是否终止公司股票上市的决定。 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公 ...

Core Viewpoint - The company, Yuancheng Environment Co., Ltd., is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false disclosures in financial reports, which poses significant risks of forced delisting due to major violations [1][3]. Financial Risks - For the first half of 2025, the company reported revenue of 82.34 million yuan and a net loss attributable to shareholders of 126.80 million yuan, which may lead to delisting risks if the annual report does not meet the requirements set by the Shanghai Stock Exchange [2]. - The company is subject to a risk warning due to its financial performance, and if the 2025 annual report does not meet the delisting criteria, the company's stock may be terminated from listing [2]. Operational Status - As of the announcement date, the company's business activities are reported to be operating normally, and the CSRC's investigation is ongoing without any conclusive findings yet [3]. - The company and its controlling shareholder are cooperating with the CSRC's investigation and will provide monthly updates on the progress of the investigation as required by the stock listing rules [3]. Risk Warnings - The company faces uncertainties regarding its ability to continue operations and liquidity risks, with multiple bank accounts frozen, totaling a significant amount in restricted funds [2].

Core Viewpoint - *ST Suwu has issued multiple warnings regarding significant trading risks and potential forced delisting due to abnormal stock price fluctuations and regulatory issues [1][3][7]. Group 1: Trading Risks - On August 27, *ST Suwu announced that its stock price had deviated significantly, with a cumulative increase of over 12% in two consecutive trading days, indicating abnormal trading activity [4]. - The stock experienced a substantial increase over five consecutive trading days, with a trading turnover rate of 20.93% on August 27, suggesting a "hot potato" trading phenomenon [4]. - The company has warned that if further significant trading anomalies occur, it will apply for a trading suspension to protect the rights of small investors [4]. Group 2: Regulatory Issues - *ST Suwu received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, indicating that the company had inflated its operating income, costs, and profits, leading to false records in annual reports from 2020 to 2023 [7]. - The company is at risk of being subjected to forced delisting due to these violations of the Shanghai Stock Exchange listing rules [7][9]. - As of July 14, *ST Suwu's stock has been under a delisting risk warning, and if the CSRC's final decision confirms the violations, the stock will be terminated from listing [9]. Group 3: Financial and Operational Status - The company conducted a self-examination and found no significant changes in its daily operations or external environment that would impact its stock price, nor any undisclosed major events [6]. - The controlling shareholder's related parties have non-operating fund occupation amounting to 1.693 billion yuan as of the end of 2023 [9]. - The company is currently facing operational challenges due to a contract termination with Regen Biotech Inc., affecting its ability to sell AestheFill products [9].

Core Viewpoint - *ST Suwu has issued a warning regarding significant trading risks and potential forced delisting due to multiple ongoing issues, including financial fraud and substantial losses in its operations [1][2][5]. Group 1: Trading Risks - The company has experienced a significant stock price increase recently, which has raised concerns about trading risks, described as "obvious signs of a hot potato" [1][5]. - Since being investigated, *ST Suwu has issued over 40 warnings about the risk of forced delisting due to major violations [5]. Group 2: Financial Misconduct - The company has been found guilty of financial fraud over several years, which has led to the issuance of an administrative penalty notice by the China Securities Regulatory Commission [2][4]. - The company is at risk of being delisted as it has violated the Shanghai Stock Exchange's regulations regarding major misconduct [2]. Group 3: Performance Decline - *ST Suwu has projected a significant loss for the first half of 2025, estimating a net profit loss of approximately 60 million to 40 million yuan [3]. - The company's medical aesthetics business has faced severe setbacks, including the termination of exclusive distribution rights for a key product, AestheFill, leading to halted sales [3]. Group 4: Financial Health - The company reported a non-operating fund occupation of 769 million yuan, which has escalated to 1.693 billion yuan, representing 96.09% of its net assets [4]. - The controlling shareholder's shares are currently frozen, indicating potential financial instability and lack of resolution for the fund occupation issue [4].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of stock trading anomalies and potential forced delisting due to violations of financial reporting standards and substantial fund occupation by its controlling shareholder [1][2][3] Stock Trading Anomalies - The company's stock price has deviated significantly, with a cumulative increase of over 12% in closing prices over two consecutive trading days (August 26 and 27, 2025) [2] - On August 27, 2025, the trading turnover rate reached 20.93%, indicating a high level of speculative trading activity [1] Company Operations and Financial Status - As of the announcement date, the company reported no significant changes in its daily operations or external environment beyond previously disclosed matters [2] - The company confirmed that there are no undisclosed major events, such as asset restructuring or significant business partnerships, that could impact its stock price [2][3] Regulatory and Legal Issues - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, 2025, for inflating revenue, costs, and profits in its annual reports from 2020 to 2023, which may lead to forced delisting [1][3] - The company has been under a delisting risk warning since July 14, 2025, due to the aforementioned violations [3] Financial Risks - The controlling shareholder's related parties have a non-operating fund occupation balance of 1.6926071 billion yuan as of the end of 2023, which poses additional financial risks [4] - The company is facing multiple delisting risks, including financial delisting and violations of major laws [2][4] Business Disruptions - The company has faced disruptions in its medical aesthetics business due to the termination of exclusive agency agreements, which has halted related operations [4] - The company is currently unable to continue selling certain products due to legal disputes arising from contract breaches [4] Board Statements - The board of directors confirmed that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange listing rules [4][5]